ALAVATTAM, Sreedhara,AMLER, Lukas C.,DE TOLEDO PELIZON, Christina H.,BENYUNES, Mark C.,CLARK, Emma L.,KWONG GLOVER, Zephania W.,MITCHELL, Lada,RATNAYAKE, Jayantha,ROSS, Graham A.,WALKER, Ru-Amir
申请号：
AU2019261666
公开号：
AU2019261666A1
申请日:
2019.11.04
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
#$%^&*AU2019261666A120191128.pdf#####ABSTRACT The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population； combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity； treating earlystage HER2-positive breast cancer； treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag； treating HER2-positive metastatic gastric cancer； treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine； treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor； and treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer. It also describes an article of manufacture comprising a vial with Pertuzumab therein and a package insert providing safety and/or efficacy data thereon； a method of making the article of manufacture； and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the application describes an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient. 11843590_1 (GHMatters) P96260.AU.310134 U.. 0 otog 00 0L 00 C C ccl U') CC (D ( r- 0 V 0 QC. 0- 0 + Qr 0 0D NO) a 0 (s C I Mc0f-ooL tT c C el/n ralu'S96~ + oM N +C 03 0
